[Systematic review of the Genomewide Association Studies (GWAS) in schizophrenia].

INTRODUCTION Heritability in schizophrenia can reach up to 80% and the risk in families is 5-10 times higher than in the general population. The large contribution of genetics in this disorder has led to a growing interest in its study. OBJECTIVES To review the findings of genetic studies known as Genomewide Association Studies (GWAS) on schizophrenia. METHOD Systematic search using Pubmed with the key words GWAS and (psychosis) or (schizophrenia). The following web pages have been reviewed: http://www.szgene.org/largescale.asp and www.genome.gov/gwastudies/. RESULTS The GWAS have focused on causal biological aspects, such as the histocompatibility complex, glutamate metabolism, apoptosis and inflammatory processes, and the immune system (TNF-β, TNFR1). Also focused in the search were the genes that modulate the appearance of secondary metabolic and cardiac effects and secondary effects in subjects with schizophrenia and on anti-psychotic treatment. In neurorecognition, over-expression of the MET proto-oncogene (MET) has been associated with a low susceptibility for schizophrenia and a better cognitive performance, as well as a lower susceptibility for the incidence of cancer. Mention is also made of the different genes that mediate in cognitive functioning depending on the anti-psychotic treatment received. CONCLUSIONS The main interests of the GWAS during the last few years have been the neurobiological pathways involved in schizophrenia. The discoveries arising from these studies have been limited. This has led to an innovative approach on the aetiological study of the disorder by studying gene-environment interactions.

[1]  J. Rice,et al.  The Internet-based MGS2 control sample: self report of mental illness. , 2010, The American journal of psychiatry.

[2]  M. Gill,et al.  Molecular pathways involved in neuronal cell adhesion and membrane scaffolding contribute to schizophrenia and bipolar disorder susceptibility , 2011, Molecular Psychiatry.

[3]  Peilin Jia,et al.  Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs , 2010, Molecular Psychiatry.

[4]  Siobhan M. Dolan,et al.  Genome-Wide Association Studies, Field Synopses, and the Development of the Knowledge Base on Genetic Variation and Human Diseases , 2009, American journal of epidemiology.

[5]  Elvira Bramon,et al.  Gene variants associated with schizophrenia in a Norwegian genome-wide study are replicated in a large European cohort. , 2010, Journal of psychiatric research.

[6]  Tony J. Simon,et al.  22q11.2 microdeletions: linking DNA structural variation to brain dysfunction and schizophrenia , 2010, Nature Reviews Neuroscience.

[7]  T. Thornton-Wells,et al.  Comparative Linkage Meta-Analysis Reveals Regionally-Distinct, Disparate Genetic Architectures: Application to Bipolar Disorder and Schizophrenia , 2011, PloS one.

[8]  Doron Lancet,et al.  DOCK4 and CEACAM21 as novel schizophrenia candidate genes in the Jewish population. , 2012, The international journal of neuropsychopharmacology.

[9]  Jessica A. Turner,et al.  Identifying gene regulatory networks in schizophrenia , 2010, NeuroImage.

[10]  D. Blackwood,et al.  Convergence of linkage, association and GWAS findings for a candidate region for bipolar disorder and schizophrenia on chromosome 4p , 2011, Molecular Psychiatry.

[11]  Peilin Jia,et al.  Common variants conferring risk of schizophrenia: A pathway analysis of GWAS data , 2010, Schizophrenia Research.

[12]  P. Visscher,et al.  Rare chromosomal deletions and duplications increase risk of schizophrenia , 2008, Nature.

[13]  Pall I. Olason,et al.  Copy number variations of chromosome 16p13.1 region associated with schizophrenia , 2011, Molecular Psychiatry.

[14]  Chris Parker,et al.  Risk of malignancy in patients with schizophrenia or bipolar disorder: nested case-control study. , 2007, Archives of general psychiatry.

[15]  Thomas W. Mühleisen,et al.  Association between genetic variation in a region on chromosome 11 and schizophrenia in large samples from Europe , 2012, Molecular Psychiatry.

[16]  Francis S Collins,et al.  A HapMap harvest of insights into the genetics of common disease. , 2008, The Journal of clinical investigation.

[17]  Thomas W. Mühleisen,et al.  Large recurrent microdeletions associated with schizophrenia , 2008, Nature.

[18]  M. King,et al.  Genetic Heterogeneity in Human Disease , 2010, Cell.

[19]  Jianxin Shi,et al.  Genetic risk sum score comprised of common polygenic variation is associated with body mass index , 2011, Human Genetics.

[20]  P. Falkai,et al.  Modification of cognitive performance in schizophrenia by complexin 2 gene polymorphisms. , 2010, Archives of general psychiatry.

[21]  J. Aldenhoff,et al.  The cross-sectional GRAS sample: A comprehensive phenotypical data collection of schizophrenic patients , 2010, BMC psychiatry.

[22]  M C O'Donovan,et al.  Analysis of 10 independent samples provides evidence for association between schizophrenia and a SNP flanking fibroblast growth factor receptor 2 , 2009, Molecular Psychiatry.

[23]  A. Corvin.  Key players in risk for schizophrenia, bipolar disorder and other neurodevelopmental brain disorders? , 2010 .

[24]  Laura Rodriguez-Murillo,et al.  Una firma genética para las enfermedades psiquiátricas complejas , 2010 .

[25]  J. Lieberman,et al.  Cross-Disorder Genomewide Analysis of Schizophrenia , Bipolar Disorder , and Depression AJP in Advance , 2010 .

[26]  M C O'Donovan,et al.  Schizophrenia susceptibility alleles are enriched for alleles that affect gene expression in adult human brain , 2012, Molecular Psychiatry.

[27]  Patrick F. Sullivan,et al.  A framework for interpreting genome-wide association studies of psychiatric disorders , 2009, Molecular Psychiatry.

[28]  B. Kirkpatrick,et al.  Metabolic profile of antipsychotic-naive individuals with non-affective psychosis , 2009, British Journal of Psychiatry.

[29]  K. Kanyas,et al.  Genome-wide association study of antipsychotic-induced parkinsonism severity among schizophrenia patients , 2009, Psychopharmacology.

[30]  Jeffrey A Lieberman,et al.  Genome-Wide Pharmacogenomic Study of Neurocognition As an Indicator of Antipsychotic Treatment Response in Schizophrenia , 2011, Neuropsychopharmacology.

[31]  J. Lieberman,et al.  Genomewide association for schizophrenia in the CATIE study: results of stage 1 , 2009, Molecular Psychiatry.

[32]  Peilin Jia,et al.  Genome-wide association study of antipsychotic induced QTc interval prolongation , 2010, The Pharmacogenomics Journal.

[33]  T. Hansen,et al.  Association analysis of PALB2 and BRCA2 in bipolar disorder and schizophrenia in a scandinavian case–control sample , 2010, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[34]  J. Wason,et al.  Comparison of multimarker logistic regression models, with application to a genomewide scan of schizophrenia , 2010, BMC Genetics.

[35]  M. Owen.  Schizophrenia aetiology: Do gene-environment interactions hold the key? , 2008, Schizophrenia Research.

[36]  M. Rietschel,et al.  New Genetic Findings in Schizophrenia: Is there Still Room for the Dopamine Hypothesis of Schizophrenia? , 2010, Front. Behav. Neurosci..

[37]  S. Potkin,et al.  Genome-wide strategies for discovering genetic influences on cognition and cognitive disorders: Methodological considerations , 2009, Cognitive neuropsychiatry.

[38]  G. Rouleau,et al.  Where are the missing pieces of the schizophrenia genetics puzzle? , 2011, Current opinion in genetics & development.

[39]  D. Rujescu,et al.  Evidence of Sex-Modulated Association of ZNF804A with Schizophrenia , 2011, Biological Psychiatry.

[40]  S. Cichon,et al.  Genomewide association studies: history, rationale, and prospects for psychiatric disorders. , 2009, The American journal of psychiatry.

[41]  Michael J. Owen,et al.  Genetics of psychosis; insights from views across the genome , 2009, Human Genetics.

[42]  B. Kirkpatrick.  Schizophrenia as a systemic disease. , 2009, Schizophrenia bulletin.

[43]  N. Craddock,et al.  Genome-wide association studies: a primer , 2009, Psychological Medicine.

[44]  Chunyu Liu,et al.  After GWAS: searching for genetic risk for schizophrenia and bipolar disorder. , 2011, The American journal of psychiatry.

[45]  Zhaoxia Yu,et al.  SNP-based pathway enrichment analysis for genome-wide association studies , 2011, BMC Bioinformatics.

[46]  A. Reis,et al.  Evaluation of risk loci for schizophrenia derived from genome‐wide association studies in a German population , 2011, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[47]  Kazuo Yamada,et al.  Genome-Wide Association Study of Schizophrenia in Japanese Population , 2011, PloS one.

[48]  P. Visscher,et al.  Common polygenic variation contributes to risk of schizophrenia and bipolar disorder , 2009, Nature.